Ken Griffin Iovance Biotherapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 311,700 shares of IOVA stock, worth $3.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

311,700

Previous 609,200 48.83%

Holding current value

$3.23 Million

Previous $9.03 Million 72.32%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$7.78 - $14.19 $6.75 Million - $12.3 Million	-867,739 Reduced 78.1%	243,258 $1.95 Million
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $6.26 Million - $14.4 Million	824,963 Added 288.41%	1,110,997 $16.5 Million
Q4 2023 Feb 14, 2024	SELL	$3.3 - $8.89 $340,233 - $916,567	-103,101 Reduced 26.49%	286,034 $2.33 Million
Q3 2023 Nov 14, 2023	SELL	$4.44 - $8.79 $4.2 Million - $8.31 Million	-945,312 Reduced 70.84%	389,135 $1.77 Million
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $11.5 Million - $19.4 Million	-2,137,584 Reduced 61.57%	1,334,447 $9.39 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $6.51 Million - $9.68 Million	1,177,989 Added 51.35%	3,472,031 $21.2 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $10.5 Million - $18.6 Million	1,862,210 Added 431.23%	2,294,042 $14.7 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $19.9 Million - $27.4 Million	-2,089,992 Reduced 82.88%	431,832 $4.14 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $15.2 Million - $43.7 Million	2,386,618 Added 1765.17%	2,521,824 $27.8 Million
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $1.37 Million - $2.12 Million	-110,752 Reduced 45.03%	135,206 $2.25 Million
Q4 2021 Feb 14, 2022	SELL	$16.55 - $27.63 $18.3 Million - $30.6 Million	-1,107,605 Reduced 81.83%	245,958 $4.7 Million
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $20.8 Million - $27.3 Million	-1,024,101 Reduced 43.07%	1,353,563 $33.4 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $26.5 Million - $53.6 Million	1,621,945 Added 214.62%	2,377,664 $61.9 Million
Q1 2021 May 17, 2021	SELL	$28.67 - $52.59 $16.3 Million - $30 Million	-570,173 Reduced 43.0%	755,719 $23.9 Million
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $967,211 - $1.73 Million	34,494 Added 2.67%	1,325,892 $61.5 Million
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $15.3 Million - $20 Million	-549,748 Reduced 29.86%	1,291,398 $42.5 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $39 Million - $58.7 Million	1,432,331 Added 350.36%	1,841,146 $50.5 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $2.01 Million - $4 Million	103,031 Added 33.69%	408,815 $12.2 Million
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $3.96 Million - $6.48 Million	220,465 Added 258.4%	305,784 $8.46 Million
Q3 2019 Nov 14, 2019	SELL	$17.99 - $26.0 $3.91 Million - $5.66 Million	-217,528 Reduced 71.83%	85,319 $1.55 Million
Q2 2019 Aug 14, 2019	SELL	$9.78 - $24.52 $16 Million - $40.1 Million	-1,636,021 Reduced 84.38%	302,847 $7.43 Million
Q1 2019 May 15, 2019	SELL	$8.41 - $11.26 $20.9 Million - $28 Million	-2,488,645 Reduced 56.21%	1,938,868 $0
Q4 2018 Feb 14, 2019	BUY	$7.51 - $11.93 $8.46 Million - $13.4 Million	1,126,352 Added 34.12%	4,427,513 $39.2 Million
Q3 2018 Nov 13, 2018	BUY	$11.25 - $17.7 $32 Million - $50.3 Million	2,841,526 Added 618.21%	3,301,161 $0
Q2 2018 Aug 10, 2018	BUY	$12.45 - $16.95 $3.29 Million - $4.48 Million	264,160 Added 135.14%	459,635 $0
Q1 2018 May 11, 2018	BUY	$8.1 - $19.5 $1.32 Million - $3.19 Million	163,531 Added 511.93%	195,475 $3.3 Million
Q4 2017 Feb 09, 2018	SELL	$6.65 - $9.25 $155,477 - $216,265	-23,380 Reduced 42.26%	31,944 $256,000
Q3 2017 Nov 09, 2017	BUY	$4.45 - $8.55 $246,191 - $473,020	55,324	55,324 $429,000

Others Institutions Holding IOVA

# of Institutions

323

Shares Held

239M

Call Options Held

1.27M

Put Options Held

1.68M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.63B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account